BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10655448)

  • 1. Re: Vitamin A analogue for breast cancer prevention: a grade of F or incomplete?
    Meyskens FL
    J Natl Cancer Inst; 2000 Feb; 92(3):274-5. PubMed ID: 10655448
    [No Abstract]   [Full Text] [Related]  

  • 2. Vitamin A analogue for breast cancer prevention: a grade of F or incomplete?
    Piantadosi S
    J Natl Cancer Inst; 1999 Nov; 91(21):1794. PubMed ID: 10547379
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Vitamin A analogue for breast cancer prevention: a grade of F or incomplete?
    Veronesi U; De Palo G; Marubini E; Costa A; Mariani L; Formelli F; Decensi A
    J Natl Cancer Inst; 2000 Feb; 92(3):274; author reply 274-5. PubMed ID: 10655447
    [No Abstract]   [Full Text] [Related]  

  • 4. Chemoprevention of breast cancer with fenretinide.
    Veronesi U; De Palo G; Costa A; Formelli F; Decensi A
    IARC Sci Publ; 1996; (136):87-94. PubMed ID: 8791119
    [No Abstract]   [Full Text] [Related]  

  • 5. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
    Veronesi U; De Palo G; Marubini E; Costa A; Formelli F; Mariani L; Decensi A; Camerini T; Del Turco MR; Di Mauro MG; Muraca MG; Del Vecchio M; Pinto C; D'Aiuto G; Boni C; Campa T; Magni A; Miceli R; Perloff M; Malone WF; Sporn MB
    J Natl Cancer Inst; 1999 Nov; 91(21):1847-56. PubMed ID: 10547391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide.
    Costa A; De Palo G; Decensi A; Formelli F; Chiesa F; Nava M; Camerini T; Marubini E; Veronesi U
    Ann N Y Acad Sci; 1995 Sep; 768():148-62. PubMed ID: 8526344
    [No Abstract]   [Full Text] [Related]  

  • 7. [-Results of ongoing breast cancer prevention studies-].
    Jungi WF
    Arch Gynecol Obstet; 1995; 256 Suppl():S116-21. PubMed ID: 8619644
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
    Ménard S; Camerini T; Mariani L; Tomasic G; Pilotti S; Costa A; De Palo G; Veronesi U
    J Natl Cancer Inst; 2001 Feb; 93(3):240-1. PubMed ID: 11158198
    [No Abstract]   [Full Text] [Related]  

  • 9. Fenretinide in the prevention of breast cancer in premenopausal women: fluke or fact?
    Pritchard KI
    Ann Oncol; 2006 Jul; 17(7):1035-6. PubMed ID: 16766581
    [No Abstract]   [Full Text] [Related]  

  • 10. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide.
    Costa A; Formelli F; Chiesa F; Decensi A; De Palo G; Veronesi U
    Cancer Res; 1994 Apr; 54(7 Suppl):2032s-2037s. PubMed ID: 8137334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fenretinide and cancer prevention.
    Torrisi R; Decensi A
    Curr Oncol Rep; 2000 May; 2(3):263-70. PubMed ID: 11122852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fenretinide and risk reduction of second breast cancer.
    Decensi A; Zanardi S; Argusti A; Bonanni B; Costa A; Veronesi U
    Nat Clin Pract Oncol; 2007 Feb; 4(2):64-5. PubMed ID: 17259924
    [No Abstract]   [Full Text] [Related]  

  • 13. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
    Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
    Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?
    Cazzaniga M; Varricchio C; Montefrancesco C; Feroce I; Guerrieri-Gonzaga A
    J Biomed Biotechnol; 2012; 2012():172897. PubMed ID: 22500077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surrogate response biomarkers in prevention research: do they point the way or lead us astray?
    Fabian CJ
    J Clin Oncol; 2009 Aug; 27(23):3734-6. PubMed ID: 19597020
    [No Abstract]   [Full Text] [Related]  

  • 16. Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial.
    Formelli F
    J Cell Biochem Suppl; 2000; 34():73-9. PubMed ID: 10762018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adiponectin: a risk biomarker and attractive target for chemoprevention.
    Fabian CJ
    J Clin Oncol; 2012 Jan; 30(2):124-6. PubMed ID: 22162567
    [No Abstract]   [Full Text] [Related]  

  • 18. Breast cancer prevention trials using retinoids.
    Decensi A; Serrano D; Bonanni B; Cazzaniga M; Guerrieri-Gonzaga A
    J Mammary Gland Biol Neoplasia; 2003 Jan; 8(1):19-30. PubMed ID: 14587861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fenretinide: a prototype cancer prevention drug.
    Malone W; Perloff M; Crowell J; Sigman C; Higley H
    Expert Opin Investig Drugs; 2003 Nov; 12(11):1829-42. PubMed ID: 14585058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
    Decensi A; Veronesi U; Miceli R; Johansson H; Mariani L; Camerini T; Di Mauro MG; Cavadini E; De Palo G; Costa A; Perloff M; Malone WF; Formelli F
    Clin Cancer Res; 2003 Oct; 9(13):4722-9. PubMed ID: 14581342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.